OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and Drug Topics. All rights reserved.
The FDA has approved Taclonex, a combination topical consisting of calcipotriene 0.005% and betamethasone dipropionate 0.064%, for the treatment of psoriasis vulgaris in adults. Warner Chilcott plans to launch the new ointment in the first half of 2006.
Related Content:
News